New eczema pill shows promise in large Real-World trial
NCT ID NCT07276620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test the drug ivarmacitinib in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). Participants take a daily pill for up to 52 weeks, with the option to adjust the dose. Researchers will measure how well the drug clears skin rashes and reduces itching, and track any side effects. The goal is to see how well the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivarmacitinib (a JAK inhibitor taken as a tablet)
What this could lead to
If successful, this could confirm ivarmacitinib as a safe and effective long-term treatment option for moderate-to-severe atopic dermatitis, helping more people manage their symptoms.
What could go wrong
This is a real-world study, not a blinded placebo trial, so results may be less definitive. Side effects of JAK inhibitors include infection risk and blood abnormalities, and the study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••